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Abstract: COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large
number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome
seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine
storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity
seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical
symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process,
based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents
to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive
measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of
inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1
blockers are most widely used for treating COVID-CS.
Key words: COVID-19, SARS-CoV-2, cytokine storm, acute respiratory distress syndrome, tocilizumab, anakinra

1. Introduction and historical background
Coronavirus disease 2019 (COVID-19) is a severe acute
respiratory syndrome that emerged in China in December
2019. After its rapid spread worldwide, the World Health
Organization (WHO) declared the situation as a pandemic
on March 11, 2020. It is a clinical syndrome caused
by a new coronavirus, called severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus similar to two other coronaviruses that have
caused fatal infections in the last two decades. The other
two coronaviruses, namely the severe acute respiratory
syndrome coronavirus (SARS-CoV) and the Middle East
respiratory syndrome coronavirus (MERS-CoV) were
responsible for fatal outcomes (Paules et al., 2020). SARSCoV-2 shows 79.5% and 50% genome-wide sequence
identity with SARS-CoV and MERS-CoV, respectively.
However, the SARS-CoV-2 spike protein exhibits a 10–20
times higher affinity for the cellular angiotensin-converting
enzyme-2 (ACE-2) receptors in humans (Wrapp et al.,
2020).
Coronaviruses (CoVs) are large, enveloped, RNA
viruses that can be divided into four types: alpha, beta,

delta, and gamma. Of these, alpha and beta CoVs are
known to infect humans and are called HCoV. The surface
spike (S) glycoprotein of coronaviruses is critical for
binding to host cell receptors. The emergence of SARSCoV and MERS-CoV followed by this third, highly
pathogenic zoonotic HCoV, illustrates the threat posed by
this viral family (Ganesh et al., 2016; Su et al., 2016; Paules
et al., 2020). However, SARS-CoV and MERS-CoV have
lost their effectiveness within time (Paules et al., 2020).
Unfortunately, the SARS-COV-2 virus continues to spread
and causes mortality and morbidity in humans without
losing its virulance, with more than 160 million confirmed
infected cases and more than 3 million deaths, reported to
date. Until now over one billion people were vaccinated
with the recently developed vaccines against the virus to.1
SARS-CoV-2 remains asymptomatic or causes mild
symptoms in most patients and is less lethal than MERSCoV. However, up to 10%–20% of cases (usually older
people with comorbidities) may develop interstitial
pneumonia acute respiratory distress or septic shock,
World Health Organization (WHO) (2021). Name of resource [online]. Website https://www.who.int/ [accessed 00 Month Year].
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which can progress to acute respiratory distress syndrome
(ARDS). In these cases, a serious disease picture is
characterized by a rapid deterioration of the patient’s
clinical condition and the development of the features
of hemophagocytic syndrome or macrophage activation
syndrome (MAS). In these patients, uncontrolled and high
secretion of proinflammatory cytokines, very high levels
of serum ferritin and CRP levels, hepatic dysfunction,
disseminated intravascular coagulation (DIC), and
hypercoagulopathy is detected (Huang et al., 2020). This
hyperinflammatory condition is similar to hemophagocytic
lymphohistiocytosis (HLH), which was initially called
secondary HLH or MAS, and also resembles the classically
known chimeric antigen receptor T cell-(CAR-T) induced
cytokine release syndrome. However, COVID-19 induced
hyperinflammatory state incorporates some differences.
For example, high serum levels of cytokines and ferritin
seen in the course of COVID-19 are milder, splenomegaly
and lymphadenopathy are not present, and even splenic
atrophy can be detected in some COVID-19 cases (Yao
et al., 2020). For these reasons, this hyperinflammatory
condition may be called a cytokine storm secondary to
COVID-19 or COVID-19 associated cytokine storm
(COVID-CS) (Samudrala et al., 2020; Soy et al., 2020;
Caricchio et al., 2021; Nigrovic et al., 2021). Since it not
possible to use the diagnostic criteria for the diagnosis
of classic HLH and MAS for COVID-CS, Caricchio et al.
(2021) from Temple University put forward new criteria to
overcome this confusion and to make an early diagnosis
of COVID-CS. This severe hyperinflammation and its
complications can lead to the death of the patient, if not
treated swiftly, and a dynamic approach in adapting the
therapy to the emerging complications is required.
Understanding
the
underlying
pathogenetic
mechanisms of COVID-19 and recognizing the broad
disease spectrum ranging from mild to severe are
fundamental requirements for an effective treatment
strategy in critically ill patients. In this respect, it is
necessary to review briefly the pathogenesis of SARSCoV-2 infection and COVID-CS, and the underlying
mechanisms.
In this article, the immunopathogenesis of COVID-19
disease, immune modalities to control the virus, and
mechanisms and management of the hyperinflammation
that occurs during the disease course will be discussed.
2. Immunopathogenesis of COVID-19
The novel coronavirus, SARS-CoV-2 is the last member
of coronaviridae that can infect humans. It has four main
structural proteins including the spike (S), membrane,
envelope, and nucleocapsid proteins. SARS-CoV-2 carries
a larger genome than any other virus known so far (26.4–
31.7 kb) (Mousavizadeh et al., 2020). The S protein, which

gives the typical shape of the virus, contains a special
binding site that allows the virus to bind to the host
cell. In the host cell, the target of the virus is the ACE2 receptor present in many organs and systems including
the heart, lungs, kidneys, and gastrointestinal tract (Chen
et al., 2020). The ultrastructural examination of the viral
S protein of SARS-CoV-2 revealed its similarity to the
S-protein of the other CoVs. S protein contains an S1
domain capable of receptor binding and an S2 domain
attached to the membrane. The S1 domain is divided into
the N and C terminal domains. In SARS-CoV and SARSCoV-2 viruses, the C terminal domain is responsible for
the binding to the ACE-2 receptor of the host. But, SARSCoV-2 has a 10- to 20-fold increased binding affinity to
ACE-2 (Bourgonje et al., 2020). This binding and the
following S-protein priming by the host cell protease transmembrane protease/serine (TMPRSS) and cathepsins in
the absence of TMPRSS permit the entry into the host cell
(Sun et al., 2020). After the virus enters the cell, the viral
RNA genome is released into the cytoplasm of the host
cell and translated into structural proteins, after which the
viral genome begins to be replicated and the whole virus
is secreted into the cytoplasm in a vesicle. These viruscontaining vesicles fuse with the plasma membrane and
release the viruses, and as the host cell disintegrates the
virus becomes attached to other cells. (Sun et al., 2020).
In humans, the ACE receptor is most commonly found
on the surface of the respiratory tract cells, particularly on
type-2 pneumocytes. The stimulation of this receptor by the
S1 domain of the SARS-CoV-2 virus downregulates ACE2 which leads to the compensatory production of high
amounts of angiotensin-2 by ACE-1 activity and causes
increased permeability in the lungs. In addition, a high
amount of proinflammatory cytokines and chemokines
are secreted from dendritic cells and macrophages that are
activated as a result of excessive and ongoing stimulation
of the immune system, as described more in detail in
the following paragraphs. This situation, if untreated
effectively, leads to more pronounced organ damage and
a hyperinflammatory state that is called COVID-CS, and
can lead to the death of the patient (Samudrala et al., 2020;
Soy et al., 2020).
3. Why cytokine storm develops in some patients with
COVID-19?
In a normal-working immune system, when pathogens,
including viruses, enter the body, their antigens are
recognized as pathogen-associated molecular patterns
(PAMPs) or microbial-associated molecular patterns
(MAMPs) by the cells of the innate immunity through the
pattern recognition receptors (PRRs). Damage or deathassociated molecular patterns (DAMPs) are expressed
or released from endangered and damaged host cells
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and include high mobility group box 1 (HMGB1) and
heat shock proteins (HSPs). DAMPs are also recognized
by PRRs, resulting in stimulation of the innate immune
system following unplanned cell death. These molecules
trigger the inflammatory response by activating the
mitogen-activated protein kinases (MAPK) and nuclear
factor of kappa light polypeptide gene enhancer in B-cells
(NF-κB) pathways (Tang et al., 2012) (Figure 1).
Different types of PRRs recognize a wide variety of
antigenic threats in the body; they may be localized on
cellular or endosomal membranes, or in the cytosol,
and serve for signaling. On the other hand, secreted
forms may also be present in the bloodstream and
interstitial fluids. The PRRs are divided into four
families: (i) toll-like receptors (TLR), (ii) nucleotidebinding oligomerization domain-like receptors (NLR),
(iii) C-type lectin receptors (CLR), (iv) RIG-1
like receptors (RLR).
TLR and RIG-1 play a major role in recognizing
viruses. TLRs are expressed mainly in immune cells and
to a lesser extent, in various other cells. Currently, 11
members of the TLR family are known. Each of these is

Figure 1. Immune response to viral pathogens.
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specialized to recognize different PAMPs/MAMPs. For
example, TLR3 and TLR9 recognize viruses. TLR3 also
controls type I interferon (IFN)-based immunity through
interferon regulating factors (IRF). Viral nucleic acids
(RNAs) generally serve as PAMPs/MAMPs, and trigger
PRRs, including endosomal TLRs 3 and 7 and cytosolic
RIG-I-like receptors (RLRs), leading to induction of
proinflammatory cytokine-inducing transcription factors
such as NF-κB, as well as activation of IRFs that mediate
type I IFN-based antiviral response to eliminate the viral
agents that threaten the body (Crow et al., 2019; Kumar
et al., 2020; Schnappauf et al., 2020). Another pathway
for antiviral activity proceeds through RLRs. The RLR
family consists of three members: retinoic acid-inducible
gene I (RIG-I), melanoma differentiation-associated gene
5 (MDA5), and genetics and physiology lab 2 (LGP2).
Additionally, RIG-I and MDA5 have two CARD domains.
Upon activation of RLRs by RNA binding, CARD interacts
with the adapter mitochondrial antiviral signal protein
(MAVS), ultimately leading to the transcription of genes
encoding type I IFNs. Type I IFNs further coordinate
cellular immune responses against virus infection and are
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therefore required for antiviral immunity (Zalinger et al.,
2015; Barrat et al., 2016; Lucherini et al., 2018; Crow et al.,
2019).
Under normal conditions, virus-infected cells are
destroyed by NK cells of innate immunity and CD8+
cytolytic T cells of adaptive immunity using various
mechanisms such as perforin-mediated granulysin
secretion and direct cytotoxicity. This leads to apoptosis
of antigen-presenting cells (APC) and related cytotoxic T
cells to prevent unnecessary activation after the antigenic
activity ends (Figure 1). If the antigenic stimulation is
persistent due to various reasons or there is a genetic or
acquired defect in lymphocyte cytolytic activity, NK and
cytolytic CD8+ T cells can no longer lyse the infected
cells, leading to uncontrolled and continuous activation of
innate and adaptive immune cells. As expected, this results
in uncontrolled secretion of many proinflammatory
cytokines, including TNF-a, IL-1, IL-6, IL-18, and IL-33,
causing a cytokine storm. In brief, defects in lymphocyte
cytolytic activity continue with increased macrophage
activity, uncontrolled immune system activation, and a
hyperinflammatory condition called COVID-CS, which

causes ARDS and multiorgan failure, and sometimes
death (Figure 2) (Huang et al., 2020; Zhang et al., 2020a).
However, severe COVID-CS which is one of the major
causes of death in COVID-19 occurs only in a minority of
the patients. In other words, hyperinflammation develops
only in some patients during COVID-19. Probably,
virus-related factors and genetically determined or
acquired defects in the host immune system, as outlined
in the following paragraphs may explain why COVID-CS
develops in some patients, although the exact answer is
not known (Huang et al., 2020; Samudrala et al., 2020; Soy
et al., 2020; Zhang et al., 2020a; Caricchio et al., 2021;
Nigrovic et al., 2021).
3.1. Virus related factors
Why the antigenic threat created by the virus cannot be
eliminated? SARS-CoV and MERS-CoV develop various
strategies to stay in the cell longer. SARS-CoV and MERSCoV can produce double-membrane vesicles that do not
have PRRs and can be hidden from host immunity by
replicating in these vesicles (Snijder et al., 2006). This
may cause antigenic persistence and insufficient viral

Figure 2. Pathogenesis and clinical findings in COVID-19 induced cytokine storm.
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clearance. The observations that virus inclusion bodies
can still be demonstrated in pulmonary alveolar cells
and macrophages up to two weeks, despite negative PCR,
supports the presence of a problem in viral clearance (Min
et al., 2016).
When compared to SARS-CoV, the receptor-binding
site (RBS) of the S1 domain in SARS-CoV-2 is highly
variable and five amino acids of the six amino acid-region
found in this S1 domain differ in the SARS-CoV-2 virus.
This provides SARS-CoV-2 with high affinity and optimal
binding to ACE-2 receptors (Samudrala et al., 2020).
Other than mutations in the RBD of the S protein, the
presence of O-linked glycans and polybasic furin cleavage
also contributes to the high affinity, rapid transmission,
replication, and infectivity of this virus (Andersen KG et
al., 2020; Walls et al., 2020).
The persistence of the SARS-CoV-2 virus in the
vascular bed may play a role in the pathogenesis of
chilblains occurring after COVID-19, and probably in
the pathogenesis of MIS-C (multisystem inflammatory
syndrome), which may develop after infection in children
and resembling Kawasaki syndrome (Colmenero et al.,
2020; Schwartz et al., 2021). In addition, the postinfectious
complaints and clinical problems, which continue after
COVID-19 and are called long COVID, and other similar
problems that persist after the acute infection, suggest that
there may be a virus or its residue in the body that cannot
be cleared (Perego et al., 2020; Ramos-Casals et al., 2021;
Writing Committee for the COMEBACK et al., 2021).
Another problem is rapid viral mutations. Although
numerous mutations have been reported to date, only five
of them are accepted as variants currently. These variants
seem to spread more easily and faster than other known
variants, which could lead to more COVID-19 cases, more
hospitalizations, and potentially more deaths. Studies so
far show that despite lower neutralizing antibody titers
produced by vaccination permitted in the USA, antibodies
may recognize these variants. In other words, although
these vaccines provide approximately 10-fold lower
neutralizing antibody titers against variants, it is thought
that they may be effective (Luchsinger et al., 2021).
3.2. Genetic defects in host defences
Genetic polymorphisms of the receptors of antiviral defense
may contribute to the severe course of viral infections,
including COVID-19. TLR3 polymorphisms have been
associated with infectious, autoimmune, and neoplastic
diseases (Skevaki et al., 2015). In previous studies, TLR3
polymorphisms are associated with severe hepatitis B and
C virus infections; currently, these polymorphisms have
also been related to COVID-19 severity (Zhang et al.,
2020a; Grolmusz et al., 2021).
Serum IFN-a levels may be found to be very low in some
COVID-19 cases due to TLR3 or IRF3 polymorphisms. In
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addition, anti-IFN-a antibodies may cause very low levels
of IFN-a in some patients. Low levels of IFN-a are related
to severe COVID-19 pneumonitis. However, innate defects
of IRF7-dependent type I IFN immunity were found in
only 3.5% of patients. Possibly, other TLRs and related
gene polymorphisms also play a role in determining the
severity of SARS-COV-2 infection (Zhang et al., 2020a).
Interestingly, TLR4, which plays a role in antibacterial
defense, can also trigger IFN-a activation and neutrophil
extracellular traps (NETS) and contribute to antiviral
defense (Khanmohammadi et al., 2021). In addition,
testosterone may increase TLR4 production, leading
to a higher cytokine response, which may be another
mechanism of higher cytokine response in males (Cicco
et al., 2020).
An increased number of circulating neutrophils
have been identified as an indicator of the severity of
COVID-19 (Guan et al., 2020). Neutrophils generate a
variety of mechanisms to eliminate invading pathogens,
including viruses. They can kill microbes not only through
phagocytosis, formation of reactive oxygen species,
degranulation, and secretion of antimicrobials, but also
through the formation of NETs, and this process is called
NETosis. NETs are networks of extracellular neutrophil
DNA fibers that bind and kill extracellular pathogens and
limit the damage of host cells (Kaplan et al., 2012). NETs
are extracellular reticulate fibers composed of DNA and
histone and containing enzymes derived from neutrophilic
granules such as myeloperoxidase (MPO) and elastase.
The NET formation is a type of programmed cell death,
different from apoptosis and necrosis. Several antigenic
stimuli including viral RNA and proinflammatory
cytokines can induce both NETs and NETosis formation.
Besides their antimicrobial effects, NETs also play a role
in the pathogenesis of a variety of diseases, including SLE,
rheumatoid arthritis, diabetes mellitus, and sepsis (Lee et
al., 2017). Furthermore, some drugs that can prevent the
development of NETosis have been shown to have positive
effects on patient survival in the course of sepsis. Recently,
Veras et al. showed, there was a high NET formation
in tracheal aspirates, lung infiltrates, and peripheral
neutrophils of patients with COVID-19, but not in the lungs
of patients who died because of heart failure. In addition,
they showed that the blocker of the PAD-4 enzyme, which
has a critical role in the formation of NETosis, may inhibit
the formation of NETs (Veras et al., 2020). The same group
also demonstrated that serine protease inhibitors blocking
the ACE-2/TMPRSS2 pathway, which has a critical role for
SARS-CoV-2 entry to cells, prevent SARS-CoV-2 induced
NETs released by neutrophils. These data suggest that NET
formation plays a role in the pathogenesis of SARS-CoV-2
and that therapies directed at this pathway may work in
preventing lung damage (Cicco et al., 2020).
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Decreased anti-SARS-CoV-2 antibody titer, decreased
specificity, and decreased neutralizing activity have been
reported in patients with MIS-C, a post-COVID-19 lifethreatening complication in children, compared with
patients with acute COVID-19 respiratory infection. The
authors claimed that younger people had dense naive T
cells located in various parts of the body and prevented
infection in organs such as the lungs with a strong immune
response and that the weaker but ongoing infection in other
regions could lead to MIS-C by getting stronger over time
(Jia et al., 2020; Weisberg et al., 2020). The presence of the
SARS-CoV-2 virus detected in the vascular bed in children
may also explain the delayed complications (Colmenero et
al., 2020; Schwartz et al., 2021). SARS-CoV-2 virus, which
takes advantage of the abovementioned mechanisms and
various disorders in the immune system, causes infection in
the upper and lower respiratory tract where the expression
of ACE-2 receptor is intense, followed by uncontrolled
infection and proinflammatory cytokine release, resulting
in hyper inflammation, serious organ damage, ARDS,
DIC, and thrombotic complications (Figure 2).
COVID-19 is also associated with a significant risk
of micro- and macrovascular thrombotic complications
such as venous thromboembolic disease, pulmonary
embolism, and stroke, which are also associated with
multiorgan failure and increased mortality. In addition
to classical prothrombotic factors, immune mechanisms
also play a role in the formation of thrombosis. TNF-ɑ,
one of the increased cytokines in the course of COVID-19,
triggers an increase in plasminogen activator inhibitor-1,
which inhibits tissue plasminogen activator, which leads
to a decrease in plasmin activity, reducing fibrinolysis.
Complement activation, cell lysis, von Willebrand factor
formation, formation of NETosis, increasing tissue factor
synthesis, and prothrombin activity may also contribute
to thrombotic tendency (Loo et al., 2021). In brief,
inadequate eradication of the SARS-CoV-2 virus due to
various combinations of viral factors and genetic defects
in host immunity may cause the occurrence of COVID-CS
in some patients.
4. Diagnosis of cytokine storm in COVID-19
Diagnosis of COVID-19 can be made by clinical
manifestations, radiologic evidence of viral pneumonia,
and PCR testing for COVID-19. On the other hand, early
diagnosis of COVID-CS is of particular importance,
because patients can be critically ill and delays in diagnosis
can lead to poor outcomes. Unfortunately, there is no
single pathognomonic clinical finding or laboratory test
to diagnose this life-threatening condition (Lei et al.,
2020). The criteria used for HLH and MAS are not suitable
for COVID-CS (Soy et al., 2021). Recently Caricchio et

al. proposed a preliminary set of criteria for predicting
COVID-CS (Caricchio et al., 2020). They defined five
obligatory criteria and a three more cluster sets containing
various parameters. According to those preliminary set
of criteria, patients should have at least one of the items
contained in all three cluster sets, in addition to these
obligatory criteria (Table). Although those preliminary set
of criteria may be useful in some patients whose general
condition is deteriorating, we believe that it is too early to
use them as definite diagnostic criteria; further studies are
needed. Simply put, COVID-CS should be considered in a
patient with a confirmed diagnosis of COVID-19, if there
is a rapid deterioration of the general condition, persistent
fever lasting than three days, progressive increase in serum
CRP, ferritin, and D-dimer values. This diagnosis and
management should be guided by a committee consisting
of at least one of the following: rheumatologist trained in
internal medicine, hematologist, clinical immunologist,
pneumologist, a specialist in infectious diseases, and
specialist of intensive care.
5. Management of cytokine storm in COVID-19
infection
Management of COVID-19 includes antiviral agents to
inhibit SARS-CoV-2 replication as well as treatment of the
potential complications including cytokine storm using
appropriate immunosuppressive and immunomodulatory
drugs to reduce systemic inflammation. As mentioned
above, COVID-CS is a hyperinflammatory state similar
to cytokine storms developing in HLH or CAR-T induced
cytokine release syndrome. However, there are also
differences, including treatment approaches. The earlier
the diagnosis of CS, the more effective the treatment is. The
rationale of the treatment of COVID-CS, which represents
a hyperinflammatory state, is to suppress the inappropriate
immune response. IL-6, IL-1, IFN-g, TNF-a, IL-8, and IL18 play a critical role in the development of the cytokine
storm but there may be additional contributory cytokines.
Corticosteroids (CCS) and targeted therapies for
certain cytokines, especially IL-6R antagonists including
tocilizumab (TCZ) and IL-1 antagonists including
anakinra are most commonly used for the treatment
of cytokine storm. On the other hand, TNF inhibitors
such as infliximab and adalimumab, IFN-γ inhibitors
such as emapalumab, and Janus kinase inhibitors such
as baricitinib and ruxolitinib are among other agents
investigated for this purpose. However, the use of
antiinflammatory therapy in severe COVID-CS poses a
critical issue. Whatever the antiinflammatory treatment
is, the timing is of utmost importance. Otherwise, trying
to reach clinical improvement through suppression of
excessive immune responses, might paradoxically decrease
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Table. Predictive criteria for cytokine storm in COVID-19 proposed by Caricchio et al. (2021)*.
Entry criteria (must be all met)
• +Signs/symptoms of COVID-19
• ±RT-PCR positive for COVID-19
• +GGO by HRCT (or chest X-ray)
• Ferritin
• C-reactive protein

Cut-off values

>250 ng/mL
>4.6mg/dL

Comments
RT-PCR positivity was not mandatory due to the high percentage of false
negatives (15%). Ferritin and CRP appeared as strong indicators of acute
inflammation in COVID-CS**.

AND (one variable from each cluster)
Cluster I
Albumin
Lymphocyte (%)
Neutrophil(absolute)

<2.8 g/dL
10.2
11.4 K/mm3

Cluster II
ALT
AST
D-dimers
LDH
Troponin I

>60 U/L
>87 U/L
>4,930 ng/mL
>416 U/L
>1.09 ng/mL

Cluster III
Anion gap
Chloride
Potassium
BUN:creatinine ratio

<6.8
>106 mmol/L
>4.9 mmol/L
>29 ratio

Neutrophils and monocytes were found to be significantly increased in
COVID-CS cases, suggesting an active role of innate immunity in COVIDCS. On the other hand, lymphocytes declined nearly to half of the lower
normal limit, suggesting that adaptive immunity in COVID-CS was
functionally depleted. Some authors suggested additionally parameters
such as NLR, MLR***.
ALT and AST indicative of liver cell damage were elevated to nearly
twice higher normal limit; Six times higher levels of D-dimers implicated
endothelial damage and thrombosis formation. Increased LDH was a sign
of cell death, while moderately elevated troponin levels suggested damage
of cardiovascular system.
These results suggested a prerenal imbalance and kidney damage. Taken
together, they reflected systemic tissue damage affecting many organs in
COVID-CS.

*: This table was inspired from Caricchio et al. (2021) with relevant comments.
**: COVID-CS: COVID-19 cytokine storm.
***: NLR: neutrophil-to-lymphocyte ratio; MLR: monocyte‐to‐lymphocyte ratio.

the clearance of the virus from the body and increase the
risk of secondary bacterial infections (Kim et al., 2021).
Finally, it should be noted that hyperinflammation in
cytokine storm is accompanied by a hypercoagulable state.
Therefore, performing thrombosis prophylaxis using an
appropriate agent such as enoxaparin is also necessary
(Kim et al., 2021).
Corticosteroids: With appropriate dosing and timing
of administration given, CCS treatment is extremely
important in the management of the cytokine storm.
Early administration of CCSs may inhibit the initiation
of the body’s immune defense mechanism, thereby
increasing the viral load and ultimately leading to adverse
consequences. Indications for CCS treatment include
the presence of predictive criteria for cytokine storm as
outlined above. Severe and critical clinical state, persistent
fever (>39 °C), acute hypoxemic respiratory failure, rapid
deterioration suggested by CT-scan findings (more than
50% of the infected area on CT-scan images within 48 h),
the requirement for mechanical ventilation, and presence
of relevant laboratory markers require CCS treatment.
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Inhibition of excessive inflammation through timely
administration of CCSs in the early stage of inflammatory
cytokine storm effectively prevents the occurrence of
ARDS and protects the functions of the patients’ organs
(Shang et al., 2020). RECOVERY trial is a cornerstone
controlled, open-label study investigating the effectivity of
oral or intravenous dexamethasone 6 mg daily for up to 10
days, compared to usual care alone. The primary outcome
was 28-day mortality. A total of 2104 patients hospitalized
with COVID-19 were assigned to receive dexamethasone
and 4321 to receive usual care. The use of dexamethasone
resulted in significantly lower 28-day mortality than usual
care among those who were receiving either invasive
mechanical ventilation or oxygen alone at randomization
but not among those receiving no respiratory support.
However, there was no evidence that dexamethasone
provided any benefit among patients who were not
receiving respiratory support at randomization, and the
results were consistent with possible harm in this subgroup.
This observation might be explained that those patients
probably represented the subgroup without cytokine
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storm, in whom dexamethasone treatment deteriorated
viral clearance (The RECOVERY Collaborative Group et
al., 2021).
The median duration of dexamethasone treatment in
that study was only seven days. An early course of three to
five days of CCSs is generally appropriate. However, many
experts use higher doses of CCSs (methylprednisolone
1–2 mg/kg/day or equivalent doses of dexamethasone)
for longer periods in patients with severe ARDS. If higher
doses of CCSs are used, the dose may be reduced to 6 mg
dexamethasone daily or equivalent as soon as improvement
occurs. Dexamethasone has a long biological half-life with
its auto-taper property and thereby prevents rebound
inflammation. The beneficial effect of dexamethasone was
also reported in CoDEX randomized clinical trial. Among
patients with COVID-19 and moderate or severe ARDS,
use of intravenous dexamethasone plus standard care
compared with standard care alone resulted in a statistically
significant increase in the number of ventilator-free days
over 28 days (Tomazini et al., 2020).
The final point statement confirming the effectivity
of CCS treatment was the result of the prospective
metaanalysis of clinical trials of critically ill patients
with COVID-19, performed by Sterne et al. (2020).
They reported that administration of systemic CCSs
was associated with lower 28-day all-cause mortality,
compared with usual care or placebo (WHO Rapid
Evidence Appraisal for COVID-19 Therapies (REACT)
Working Group et al., 2020).
On the other hand, we believe that if anticytokine
treatment targeting IL-6 or IL-1 will be used later, very
high doses of CCS should be avoided to reduce potential
complications of secondary opportunistic bacterial or
fungal infections.
Inhibition of interleukin-6 signaling: IL-6 is an important
proinflammatory cytokine secreted from macrophages and
has pleiotropic effects. It is induced by infection or tissue
injury and promotes the production of various acute-phase
proteins in hepatocytes and induces the differentiation of
immune cells, such as B and T cells. Besides, IL-6 is involved
in the metabolism of iron by inducing hepcidin which
decreases iron absorption, to make a microenvironment
prohibitive against infection. Taken together, in priming
inflammatory responses and activating adaptive immunity
against infection or injury IL-6 is a key cytokine (Tanaka et
al., 2014). Not only significantly elevated serum IL-6 levels
were noted in patients with COVID-19, but predictivity
of high IL-6 for poor outcomes in COVID-19 was also
reported. It was reported that nonsurvivors had higher
IL-6 levels than survivors, and high levels of IL-6 predicted
the risk of requiring mechanical ventilation (Zhou et al.,
2020). Furthermore, a recent prospective cohort study
indicated that high levels of IL-6 and D-dimer reflected

systemic inflammation and thrombotic condition and
predicted in-hospital mortality of COVID-19 (Cummings
et al., 2020).
TCZ is a humanized anti-IL-6 receptor monoclonal
antibody, inhibiting IL-6. TCZ is currently used not only
for the therapy of various autoimmune rheumatological
diseases including rheumatoid arthritis, temporal arteritis,
and Takayasu arteritis but also for the treatment of the
cytokine storm which may be induced by CAR-T treatment.
Based on these observations and the abovementioned role
of IL-6 in patients with severe SARS-CoV-2 infection
complicated with cytokine storm and ARDS, TCZ
treatment was also tried in these patients.
Retrospective studies from China reported the
resolution of fever and hypoxemia, and improvement in
serum CRP levels and pulmonary CT findings (Xu et al.,
2020). Other studies and clinical trials also supported these
observations (Toniati et al., 2020; Fu et al., 2020; Zhang
et al., 2020b; Colaneri et al., 2020). A recent retrospective
cohort study of 1351 patients with COVID-19 and
pneumonia showed that TCZ significantly reduced the
mechanical ventilation risk or death (Campochiaro et al.,
2020). In an observational study of 154 patients requiring
mechanical ventilation, TCZ reduced the risk of death by
45% (Somers et al., 2020).
In the EMPACTA trial, 389 hospitalized patients
with COVID-19 pneumonia who were not receiving
mechanical ventilation, were randomized and TCZ was
reported to reduce the likelihood of progression to the
composite outcome of mechanical ventilation or death
(Salama et al., 2021).
However, there are also studies with negative results. In a
randomized, double-blind, placebo-controlled trial, Stone
et al. reported that TCZ was not effective for preventing
intubation or death in moderately ill hospitalized patients
with COVID-19 (Stone et al., 2020).
For the treatment of cytokine storm, the recommended
TCZ dose is 8 mg/kg IV as single or divided two doses
by 12–24 h intervals (maximum dose 800 mg). Similar to
CCSs, admission of TCZ should also be on time; serum
procalcitonin levels should be normal and the presence of
any active infection should be excluded. Because the most
fearful adverse effect of TCZ is the tendency for general
infections, as also reported in clinical studies. Since serum
CRP levels and some of the clinical signs of infections
are depressed as the result of IL-6 inhibition, diagnosis
of infections may be difficult. Other potential adverse
effects of TCZ include hepatotoxicity, hyperlipidemia,
leucopenia, and the possibility of diverticulitis.
Inhibition of interleukin-1 signaling: IL-1 family is a group
of 11 cytokines that plays a central role in the regulation
of immune and inflammatory responses to infections
or various non-infectious insults. IL-1α, IL-1β, and IL-
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18 are outstanding members of this family. Following
inflammasome activation, the caspase 1 enzyme converts
pro-IL-1β and pro-IL-18 to IL-1β and IL-18, respectively
(Dinarello et al., 2013) (Figure 2). SARS-CoV-2 may cause
not only a cytokine storm where IL-1β and IL-18 play
important roles, but also may cause pyroptosis, a form
of cell death that is triggered by proinflammatory signals
and associated with inflammation. A cardinal feature
of pyroptosis is the requirement for caspase-1 activation,
and cells undergoing pyroptosis release increased amounts
of IL-1β and IL-18 (Ferreira et al., 2021).
Taken together, inhibition of IL-1β may be helpful
in patients developing a cytokine storm (Mehta et al.,
2020). IL-1 Receptor agonist (IL-1Ra) is also a member
of the IL-1 family and serves as the natural inhibitor of
both IL-1α and IL-1β. Anakinra is the recombinant
form of IL-1Ra (rHIL-1Ra) and is the first IL-1 blocking
biologic agent produced. Anakinra blocks the binding
of both IL-1α and IL-1β to IL-1R, thereby inhibiting the
proinflammatory effects of both IL-1α and IL-1β. Anakinra
is currently used in the treatment of FMF and some other
autoinflammatory diseases. Since anakinra is a modified
form of the physiologic inhibitor, it may be expected to
be rather safe relative to other agents in the same line.
However, the tendency to infections is also a concern for
anakinra. Another IL-1 inhibitor, canakinumab which is a
human monoclonal antibody neutralizing IL-1ß, has also
been used for similar indications with the advantage of
prolonged action (Dinarello et al., 2013).
A few studies have suggested beneficial effects with the
use of anakinra in COVID-19 (Huet et al., 2020; Cavalli et
al., 2021). A recent retrospective cohort study of patients
with COVID-19 and ARDS showed that high-dose
anakinra could be used safely and improved respiratory
function. Another prospective cohort study of patients
with severe COVID-19 pneumonia demonstrated that
anakinra reduced the need for mechanical ventilation
and mortality without serious side effects (Huet et al.,
2020). Although both studies showed promising results
for anakinra on severe COVID-19, there are also negative
clinical trials. In the multicentre, open-label, Bayesian
randomized CORIMUNO-ANA-1 clinical trial, anakinra
did not improve the outcomes, which were defined as the
proportion of patients who died or needed non-invasive or
mechanical ventilation by day 4 and survival without the
need for mechanical or noninvasive ventilation (including
high-flow oxygen) at day 14 (The CORIMUNO-19
Collaborative Group et al., 2021). Further randomized
clinical trials are obviously needed.
Anakinra has a short half-life (about 4–6 h) and the
recommended dose used in FMF (100–200 mg/day SC)
is not sufficient for the treatment of the cytokine storm
occurring in COVID-19. Although even in some clinical
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randomized COVID trials, anakinra was given for 3–5
days at lower doses, recent data favors the use of higher
doses of anakinra (10 mg/kg per day divided twice daily)
SC or with IV infusion until clinic benefit was achieved
(King et al., 2020). Commonly, a daily titration of the
anakinra based on the clinical and laboratory parameters
is recommended as expert opinion.
The bioavailability of SC injections is 95% with a halflife of 4–6 h. In the presence of renal failure (GFR < 30 mL/
min), the dose should be reduced. However, the hepatic
disease does not require dose adjustment. Unlike TCZ,
anakinra does not inhibit CRP synthesis directly, therefore
serum CRP levels can be used to follow up systemic acute
phase response (King et al., 2020).
Comparison of IL-6 versus IL-1 inhibition in cytokine
storm of COVID 19: In a cohort study performed
by Cavalli et al. (2021), IL-1 and IL-6 inhibition were
compared with standard management in patients with
COVID-19 developing respiratory insufficiency and
hyperinflammation. The primary endpoint was survival,
and the secondary endpoint was a composite of death
or mechanical ventilation. Among 392 patients included
in this study, 275 received only standard care, while
62 received anakinra and 55 received tocilizumab or
sarilumab. The main finding of this study was that IL-1
inhibition with anakinra, but not IL-6 inhibition with,
significantly reduced mortality in the overall population
of in-hospital patients with COVID-19, respiratory
insufficiency, and hyperinflammation. Protective effects of
IL-6 inhibition were only observed only in patients with
very high serum CRP at baseline, whereas both IL-1 and
IL-6 inhibitors were more effective in patients with low
serum lactate dehydrogenase at baseline. There was no
difference in adverse clinical outcome risk both in patients
treated with IL-1 inhibition or IL-6 inhibition, compared
to the rest of the patients who did not receive interleukin
inhibitors (Cavalli et al., 2021).
Based upon these findings, the authors suggested that
the potential benefit of interleukin inhibition is highest in
the early phases of the disease, characterized by rampant
inflammatory activation but progressively fades in more
advanced stages characterized by extensive disease burden
and tissue damage. The hypothesis of the greater efficacy of
anakinra in early phases of disease is in line with previous
studies which reported increased survival in macrophage
activation syndrome following early intervention with
IL-1 blockade (Cavalli et al., 2021).
If IL-1 blockade is really more beneficial than IL-6
inhibition, this may be due to the upstream expression
of IL-1 compared to IL-6. In other words, blocking
IL-1 signaling may also indirectly block IL-6. Another
possibility is related to the endotheliopathy associated
with COVID-19 and the release of IL-1α, which may
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be inhibited by anakinra (Cavalli et al., 2021). The
question of whether immunomodulatory therapies
improved survival in patients with COVID-19 cytokine
storm was also investigated by Narain et al., on behalf
of the Northwell COVID-19 Research Consortium. The
retrospective comparative survival analysis showed that
the combination of CCSs with TCZ had superior survival
outcomes when compared with standard treatment as
well as treatment with CCSs alone or in combination
with anakinra. Furthermore, CCS use either alone or in
combination with TCZ or anakinra was associated with
reduced hospital mortality CCS compared with patients
receiving standard treatment (Narain et al., 2021).
Langer-Gould et al. (2020) also examined outcomes
among patients who were treated with anakinra or TCZ for
COVID-19 -related cytokine storm. In this retrospective
cohort study, initial data showed the superiority of anakinra.
However, after accounting for differences in disease
severity at treatment initiation, this apparent superiority of
anakinra over TCZ was no longer statistically significant.
They concluded that prompt identification and treatment
of COVID19 cytokine storm before intubation might be
more important than the specific type of antiinflammatory
treatment. They also noted that randomized controlled
trials of targeted anticytokine treatments and CCSs should
report the duration of cytokine storm in addition to clinical
severity at randomization (Langer-Gould et al., 2020).
Since plasma concentrations of cytokines including
IL-1 and IL-6 exhibit diurnal variations, reaching higher
concentrations in the afternoon than in the morning,
the timing of drug administration in cytokine-targeted
therapy is also important (Kim et al., 2021).
Inhibition of TNF-α signaling: TNF-α is an important
proinflammatory cytokine primarily produced by
activated macrophages and contributes to the COVID-19
hyperinflammatory state. Besides, TNF-α induces NETs
release, or NETosis, whereby neutrophils release sticky
extracellular traps that help limit the spread of infection
as mentioned above. SARs-CoV-2 virus directly promotes
NETosis, thereby activating both platelets and the clotting
cascade, leading to thrombi. Besides, NETosis induces
pulmonary epithelial cell death, leading to alveolar damage
and fibrosis in COVID-19 patients. Of relevance, antiTNF therapy may not only inhibit the hyperinflammatory
state but also may reduce NET formation in COVID-19
patients (Robinson et al., 2020). A recent interesting
study showed that TNF-α mediated acute lung injury
was reduced by using an aptamer targeting TNF-α (Lai et
al., 2019). Since acute lung injury is also a characteristic
finding in COVID-19, this study also supports the possible
benefit of anti-TNF agents in the treatment of the cytokine
storm of COVID-19. However, current data is limited,
and there are a few small ongoing clinical trials, including

CATALYST, ACTIV-1, and AVID-CC, that infliximab and
adalimumab are investigated for this purpose (Robinson
et al., 2020). On the other hand, observational human
data, including small case series and larger databases,
have shown a possible benefit of maintenance anti-TNF
therapy in patients with COVID-19 (Brenner et al., 2020;
Gianfrancesco. et al., 2020; Mahil et al., 2021). After
controlling for important confounders, patients using
anti-TNF therapy for the underlying rheumatic disease
were found to have significantly less hospitalization need
related to COVID-19, compared to those without antiTNF inhibitor therapy. Safety of maintenance anti-TNF
treatment was also reported in cohorts of patients with
inflammatory bowel disease (IBD). However, selection
bias and channeling bias (confounding by indication)
should be considered while interpreting this data. Possibly,
patients with certain characteristics that put them at higher
risk for infection are not prescribed anti-TNF agents
(Robinson, et al., 2020). In brief, although observational
data on anti-TNF use that must be interpreted with
caution are suggestive of a therapeutic benefit in patients
with COVID-19, results of randomized controlled trials
(RCTs) are needed to confirm this benefit.
Inhibition of IFN-γ signaling: IFN-γ is secreted mainly
by macrophages, NK cells, and T cells, and is among the
major effector cytokines in COVID-CS. Although the use
of emapalumab, an anti- IFN-γ monoclonal antibody to
treat primary HLH was approved by the FDA in 2018,
and several clinical trials showed clinical efficacy without
severe side effects, no significant trials support the use of
IFN-γ inhibitors in COVID-19 yet (Kim et al., 2021).
Inhibition of JAK/STAT pathway: The Janus kinase-signal
transducer and activator of transcription (JAK/STAT)
pathway is important in mediating the effects of various
cytokines and growth hormones. JAK inhibition might
effectively suppress the cytokine storm because it can
nonselectively inhibit the activity of many cytokines (Seif
et al., 2020). However, inhibition of type I IFNs may also
impede antiviral immunity (Favalli et al., 2020). On the
other hand, JAK inhibition in COVID-19 may also reduce
the entry of SARS-CoV-2, in the early phase of infection.
SARS-CoV-2 enters the body through ACE-2 on alveolar
type 2 cells in the lungs, and several regulators including
AP2-associated protein kinase-1 (AAK1) are involved
in mediating endocytosis and intracellular transport
through ACE-2. Several JAK inhibitors including
baricitinib, ruxolitinib, and fedratinib, are inhibitors of
AAK1. Therefore, they may impede the cellular entry and
proliferation of SARS-CoV-2. Since tofacitinib cannot
inhibit AAK1, this agent is not recommended for this
purpose (Richardson et al., 2020; Seif et al., 2020; Kim et
al., 2021). Based upon this basic data, Stebbing et al. (2020)
suggested that baricitinib 2–4 mg daily may be combined
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with antiviral treatment in severe COVID-19 infections. A
recent multicentered RCT of ruxolitinib in patients with
COVID-19 noted faster clinical improvement with the
drug, although the results lacked statistical significance
(Cao et al., 2020a). Another multicentered retrospective
study demonstrated that baricitinib reduced the rate of
intensive care unit admission and fatality and increased
discharge rates (Cantini et al., 2020). Besides the tendency
for general infections, inhibition of antiviral type I IFN
production remains a disadvantage as pointed out above.
Type I interferon-based therapies: Physiologic antiviral
defense performed by type I interferons including IFN-a
and IFN-b seems to be inhibited in COVID-19 infections.
The reduction in type I IFNs, may be a consequence of
generalized immunosuppression induced by high viral
load. It has been shown that severe and critical patients
displayed lower activity and the diminished response
of type I IFNs compared to mild to moderate patients
(Bastard et al., 2020; Zhang et al., 2020a). Since coronavirus
inhibits the production of IFN-β1-a from inflammatory
cells, usage of IFN-β1-a may be an effective option to
increase antiviral immunity (Kow et al., 2020). Baghaei et
al. (2021) conducted a retrospective study in adult patients
hospitalized with the diagnosis of COVID-19. They
compared the combination of three doses of 12 million
international units of IFN-β1-a plus Lopinavir 400 mg
and Ritonavir 100 mg every 12 h in 152 patients with only
Lopinavir/Ritonavir combination in 302 age- and sexmatched control patients for 14 days. All patients received
common standard care. The all-cause mortality rate in the
case and control groups was 11% and 13%, respectively,
with no significant difference between the two groups.
These findings were consistent with the interim findings
from the World Health Organization’s Solidarity Trial
investigating the efficacy of four repurposed antiviral drugs
including IFN-β1-a (WHO Solidarity Trial Consortium et
al., 2020). The Solidarity Trial also reported no significant
difference in the risk of death between patients with
COVID-19 who received IFN-β1-a compared to the
control group. Although these results are disappointing
for IFN-β1-a, Kow et al. commented that it might be
premature to discard interferon-based therapies in our
armamentarium against COVID-19 (Kow et al., 2020).
They reported that interferon-based therapies might
only be effective for selected patients having deficiencies
in type I interferons, who harbored mutations in the
genes related to the toll-like receptor 3 and interferon-I
signaling pathways, or those who had autoantibodies that
recognized type I interferons. The route of administration
of interferon-based therapies may also play a factor. Since
the bioavailability via the subcutaneous route is only
approximately one-third of that via the intravenous route,
the intravenous route of administration can optimize
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the distribution to the pulmonary vasculature. Indeed,
nebulized interferon-based therapy may even provide
more targeted actions, and thus more favorable clinical
responses. A randomized controlled trial reported that
patients with COVID-19 who received inhaled nebulized
IFN-β1-a had greater clinical improvement compared to
control groups (Monk et al., 2020). In addition, the timing
of treatment is critical where interferon-based therapy
should preferably be administered in the early stage of
the disease. We also agree with Kow et al. and believe that
future trials involving interferon-based therapies would
give better results if selected patients with concurrent
deficiencies in type I interferons were selected, and
intravenous or inhalational route of administration is
chosen in the early course of the disease.
Therapeutic plasma exchange (TPE): Besides inhibiting
cytokines directly, cytokine removal by TPE, blood
purification using continuous renal replacement therapy
or extracorporeal cytokine removal are other options.
TPE may also be considered for the treatment of COVIDCS. Most of the data about TPE comes from studies
from secondary HLH and severe sepsis and is somewhat
controversial. However, rapid, and nonselective removal
of cytokines may help reduce the unfavorable effects
of the cytokine storm and may improve the function
of monocytes and/or macrophages, thereby reversing
immune-mediated damage to the lungs. However, there
are several clinical issues with the use of TPE in COVIDCS, including risks of bleeding, catheter infection,
electrolyte imbalances, and unpredicted anaphylactic
shock due to the use of blood materials. Besides, the use
of non-convalescent plasma as a substitution fluid could
reduce protective antibodies against SARS-CoV-2. Finally,
the cost and technical problems and need for qualified
staff are important issues. Therefore, on-time TPE may be
considered only in selected cases presenting with COVIDCS, and convalescent plasma should be preferred as the
substitution fluid (Kim et al., 2021).
Convalescent plasma: The rationale for using convalescent
plasma is to provide passive immunization to control
the evolution of the disease until a specific immune
response is established in the infected person. In general,
early use of convalescent plasma, before critical illness
develops, may be an important predictor of the efficacy
of passive immunotherapy for that pathogen (Katz et al.,
2021). Observational studies have consistently shown
that convalescent plasma has an adequate safety profile
in patients with COVID-19. An exploratory analysis in
4330 patients showed no significant difference in 7-day
mortality between patients who received high-titer
convalescent plasma and those who received low-titer
convalescent plasma in the overall population. However,
the superiority of high-titer convalescent plasma was seen
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in the predefined subgroup of nonintubated patients.
In this subgroup, 20% lower 7-day mortality was 14%,
versus 11%, in patients receiving high titer versus low
titer convalescent plasma, respectively (p = 0.03) (Huang
et al., 2020). A similar efficacy analysis from the Mayo
Clinic included 3082 participants and reported that the
30-day mortality rate was 29.1% in the low-titer group
and 24.7% in the high-titer group; the difference did not
reach statistical significance (Joyner et al., 2020). However,
a post hoc subgroup analysis in this study also suggested
a benefit of high-titer plasma in patients who received
plasma within 3 days after COVID-19 diagnosis, probably
confirming the importance of early therapy.
Recently Simonovich et al. (2021) randomly assigned
hospitalized adult patients with severe COVID-19
pneumonia in a 2:1 ratio to receive convalescent plasma
or placebo. The primary outcome was the patient’s clinical
status 30 days after the intervention, as measured on a
six-point ordinal scale ranging from total recovery to
death. A total of 228 patients were assigned to receive
convalescent plasma and 105 to receive placebo. At the
end of 30 days, no significant differences were observed in
clinical status or overall mortality between patients treated
with convalescent plasma and those who received placebo
(Simonovich et al., 2021).
While using convalescent plasma, possible adverse
effects including fluid overload, transfusion-associated
acute lung injury, and allergy should be considered.
However, the benefits of convalescent plasma would
outweigh its risks; and observational studies have been
more positive than randomized trials. This is possibly due
to the use of convalescent plasma to critically ill patients
in the intensive care unit in clinical trials. However,
convalescent plasma should be used as early as possible
in the course of infection (preferably within 3 days after
diagnosis) to achieve the best outcomes.
This statement was also confirmed by Libster et al.
(2021), who investigated whether early high-titer plasma
therapy might prevent severe Covid-19 in older adults.
They made a double-blind trial, comparing 250 mL
of convalescent plasma with an IgG titer greater than
1:1000 against SARS-CoV-2 spike (S) protein with saline
placebo in patients who were 65 to 74 years of age and had
prespecified coexisting conditions and in patients who
were 75 years of age or older with or without coexisting
conditions. The patients received convalescent plasma or
placebo less than 72 h after symptom onset. They observed
no serious adverse events and concluded that early
administration of high-titer convalescent plasma against
SARS-CoV-2 to mildly ill infected older adults reduced the
progression of COVID-19. Younger high-risk patients and
certain immunodeficient patients in early disease should

be considered convalescent plasma as well (Libster et al.,
2021).
Intravenous immunoglobulin (IVIG): IVIG is a blood
product prepared from the serum pooled from thousands
of healthy donors. IVIG preparations mainly consist
of IgG1 and IgG2 subclasses, however, trace amounts
of IgA and IgM may also be found. In clinical practice,
IVIG is used in patients with immune deficiencies for the
treatment of infectious diseases, as well as in treatmentresistant patients with autoimmune diseases as an
immunomodulatory agent. However, in COVID-19, the
actual role of IVIG is not to boost the immune system.
In the presence of coexisting immunodeficiency, IVIG
serves to solve this problem, but the most important
action of IVIG is pleiotropic immunomodulating actions,
involving both innate and adaptive immunity, to suppress
a hyperactive immune response that is seen in some
patients (Tzilas et al., 2020).
IVIG is generally used 0.3–0.5 gr/kg/day for five days.
Besides case reports, retrospective case series, and small
observational studies, there are also ongoing randomized,
open‐label, controlled, single, or multicenter trials (Cao
et al., 2020b; Moradimajd et al., 2021). In a retrospective
study of 58 cases with severe or critical illness due to
COVID-19, early administration of IVIG was associated
with reduced ventilator use, reduced hospital and
intensive care unit length of stay, and improved 28-day
mortality (Xie et al., 2020). Similarly, Herth et al. reported
that IVIG treatment not only improved the clinical state
of patients with moderate to severe COVID-19 infection
but also reduced the length of hospital stay. They observed
that the earlier IVIG was given, the shorter the length of
hospital stay was (Herth et al., 2020). Since the initiation
of the cytokine storm generally takes place 5–7 days after
initiation of symptoms and represents the time window in
which immunomodulation is likely to be most beneficial,
selecting the appropriate patients and early administration
of IVIG are obviously very important (Tzilas et al., 2020).
Although the general impression of IVIG treatment
is favorable, there are many limitations in evaluating
clinical improvements using IVIG therapy in patients with
COVID‐19. These limitations include a small number of
patients, the combined use of IVIG with antimicrobial
drugs and corticosteroids, variations in dosage and timing
for IVIG injection, and lack of careful evaluation of the
clinical results. Moradimajd et al., 2021). Therefore, it is
not possible to make a correct judgment on the therapeutic
effect of IVIG in patients with COVID‐19.
Finally, possible adverse effects of IVIG should also
be considered. The mild adverse effects include flushing,
headache, malaise, fever, chills, fatigue, and lethargy. Some
of the serious side effects of IVIG therapy include hemolytic
anemia, thrombosis, arrhythmia, aseptic meningitis, renal
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impairment, and transfusion-related acute lung injury
(Moradimajd et al., 2021). Anticoagulation and hydration
should not be overlooked since COVID-19 patients have
an increased tendency towards thrombosis during IVIG
treatment.
Venous thromboembolism (VTE) prophylaxis: Most
patients with a cytokine storm due to COVID-19 infection
seem to be extremely hypercoagulable. This would support
a potential role for VTE prophylaxis in COVID-19
infection. Enoxaparin 30 SC mg bid is suggested as the
preferred dose for VTE prophylaxis in critically ill patients
with COVID-19. Enoxaparin 30 mg SC bid should also
be considered for VTE prophylaxis in hospitalized wardbased patients. Higher doses of anticoagulant prophylaxis
(enoxaparin 0.5 mg/kg BW SC bid) may be considered in
patients with moderately elevated D-dimer (1500 ng/mL)
and for patients with weight above 100 kg or BMI above
40 kg/m2. Factor Xa level 4 h after the third dose may be
checked, targeting a level of 0.5–0.8 IU/mL (Bikdeli et al.,
2020).
Colchicine: Colchicine is an antiinflammatory and
immunomodulatory agent, commonly used for the
treatment of gout, FMF, and Behçet’s syndrome for a
long time. The main action of colchicine is to impede the
function of neutrophils, and it has the effect of inhibiting
IL-1ß activity by inhibition of the inflammasome complex.
Colchicine was suggested to be useful for the treatment
of some complications of COVID-19 infection, based
on its ability to inhibit IL-1 production. however phase
3, multicenter, randomized, double-blind, placebocontrolled multicenter COLCORONA (colchicine
coronavirus SARS-CoV-2) trial failed to show the efficacy
of colchicine in adult patients diagnosed with COVID-19
infection; but, these results were not confirmed and remain
elusive (Salah et al 2021). In addition, the colchicine arm
of the long-standing RECOVERY trial was suspended for
new patients because of ineffectiveness.
Other therapeutic options: Some clinicians proposed to
use stem cells or low-dose radiation therapy of the lungs
to control the hyperinflammatory state to establish an
immune-modulation through the regulatory effects on
specialized immune cells in severe COVID-19. Several
drugs including peroxisome proliferator-activated
receptors (PPARs) agonists, cyclooxygenase (COX)
inhibitors, and sphingosine-1-phosphate receptor 1 (S1P1)
which have been experimentally shown to be effective
in reducing cytokine storm associated with influenza
infection, may also be considered to use for severe
COVID-19 in the future. Use of nanomedicine including
liposomes or synthetic nanoparticles to modulate
macrophage dysfunction and to inhibit dysregulated
macrophages can be a novel therapeutic approach for
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the treatment of the cytokine storm (Kim et al., 2021).
However, all of these options are currently experimental,
and the data is limited.
Although it may not play a direct role in the treatment
of hyperinflammatory state in COVID-19, recent trends
for inhibition of coronavirus cell entry deserve attention. It
has been demonstrated that ACE-2 is the cellular receptor
that SARS-CoV-2 uses for entering the cell. Recently,
a TMPRSS2 inhibitor was approved for clinical use for
blocking entry and might constitute a treatment option
(Hoffmann et al., 2020).
6. Discussion and conclusion
It seems that the COVID-19 pandemic will occupy the
world agenda further for a long time. Although it does
not cause serious illness in the majority of the patients,
especially elderly patients with comorbidities are prone to
a more severe and possibly lethal disease course caused by
a hyperinflammatory state known as COVID-CS.
Although exact pathogenesis of COVID-CS is not
known, insufficient viral clearance due to viral factors
and genetic defects in host defense, resulting in strong
cytokine response and hyperinflammation play critical
role (Snijder et al., 2006; Min et al., 2016; Colmenero et al.,
2020; Schwartz et al., 2021).
The diagnosis of COVID-19 is based on relatively
constant clinical signs, findings, laboratory tests, and
imaging techniques, while the diagnosis of COVID-CS
depends on emerging findings during the clinical course.
We believe that COVID-CS should be considered in a
patient with a confirmed diagnosis of COVID-19, and
a rapid deterioration of the patient with the presence of
persistent fever lasting more than three to four days,
progressive increase in serum CRP, ferritin, and D-dimer
values.
Therapy of COVID-19 consists of antiviral agents
to inhibit SARS-CoV-2 replication as well as treatment
of COVID-CS with appropriate immunosuppressive
and immunomodulatory drugs to reduce the systemic
inflammation as the main cause of organ damage. CCS
and targeted therapies for cytokine blocking, such as IL6R antagonists and IL-1 inhibitors are most commonly
used for the treatment of COVID-CS. Independent of
the choice of antiinflammatory treatment, the timing
to initiate these drugs is very important. Additionally,
anticoagulant therapy should also be initiated because of
tendency towards hypercoagulability (Loo et al., 2021).
In conclusion, early diagnosis and appropriate effective
treatment of COVID-CS are of vital importance, and
multidisciplinary approach is obviously necessary.
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